Market Closed -
Nasdaq
16:00:00 2024-05-02 EDT
|
5-day change
|
1st Jan Change
|
51.69
USD
|
+2.46%
|
|
+6.21%
|
+48.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
1,021
|
1,011
|
1,609
|
1,080
|
2,361
|
3,820
|
-
|
Enterprise Value (EV)
1 |
1,021
|
1,011
|
1,609
|
1,080
|
2,361
|
3,820
|
3,820
|
P/E ratio
|
70
x
|
-67.5
x
|
65.5
x
|
111
x
|
695
x
|
99.4
x
|
68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.88
x
|
0.94
x
|
1.22
x
|
0.76
x
|
1.46
x
|
2.18
x
|
2.02
x
|
EV / Revenue
|
0.88
x
|
0.94
x
|
1.22
x
|
0.76
x
|
1.46
x
|
2.18
x
|
2.02
x
|
EV / EBITDA
|
6.22
x
|
7.25
x
|
7.35
x
|
5.61
x
|
10.2
x
|
14.2
x
|
12.8
x
|
EV / FCF
|
33.8
x
|
7.24
x
|
139
x
|
40.1
x
|
53.3
x
|
49.7
x
|
41
x
|
FCF Yield
|
2.96%
|
13.8%
|
0.72%
|
2.5%
|
1.87%
|
2.01%
|
2.44%
|
Price to Book
|
6.73
x
|
6.1
x
|
7.04
x
|
3.26
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
50,272
|
51,636
|
53,437
|
57,361
|
67,895
|
73,896
|
-
|
Reference price
2 |
20.30
|
19.57
|
30.11
|
18.83
|
34.77
|
51.69
|
51.69
|
Announcement Date
|
20-03-12
|
21-03-08
|
22-03-01
|
23-03-01
|
24-02-29
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,154
|
1,072
|
1,315
|
1,430
|
1,617
|
1,755
|
1,894
|
EBITDA
1 |
164.1
|
139.5
|
218.9
|
192.5
|
232.3
|
268.6
|
298.9
|
EBIT
1 |
69.88
|
35.68
|
82.55
|
46.36
|
98.7
|
121.7
|
144.1
|
Operating Margin
|
6.05%
|
3.33%
|
6.28%
|
3.24%
|
6.11%
|
6.94%
|
7.61%
|
Earnings before Tax (EBT)
1 |
29.67
|
-0.854
|
58.88
|
42.97
|
38.81
|
85.45
|
110.6
|
Net income
1 |
14.76
|
-14.84
|
24.73
|
10.65
|
3.044
|
38.7
|
56.72
|
Net margin
|
1.28%
|
-1.38%
|
1.88%
|
0.74%
|
0.19%
|
2.2%
|
3%
|
EPS
2 |
0.2900
|
-0.2900
|
0.4600
|
0.1700
|
0.0500
|
0.5200
|
0.7600
|
Free Cash Flow
1 |
30.17
|
139.6
|
11.62
|
26.97
|
44.26
|
76.89
|
93.27
|
FCF margin
|
2.61%
|
13.02%
|
0.88%
|
1.89%
|
2.74%
|
4.38%
|
4.93%
|
FCF Conversion (EBITDA)
|
18.38%
|
100.09%
|
5.31%
|
14.01%
|
19.05%
|
28.63%
|
31.2%
|
FCF Conversion (Net income)
|
204.45%
|
-
|
46.98%
|
253.2%
|
1,454.11%
|
198.7%
|
164.43%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-12
|
21-03-08
|
22-03-01
|
23-03-01
|
24-02-29
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
332.7
|
333.2
|
341.8
|
354.4
|
350
|
383.9
|
390.6
|
403.7
|
402
|
420.4
|
421.7
|
438.5
|
434.2
|
460.5
|
459
|
EBITDA
1 |
62.28
|
54.51
|
38.13
|
51.34
|
45.77
|
57.23
|
48.16
|
60.44
|
57.92
|
65.81
|
55.29
|
68.66
|
68.19
|
76.43
|
64.5
|
EBIT
1 |
32.57
|
4.652
|
-1.719
|
19.56
|
6.924
|
21.6
|
6.671
|
24.44
|
43.25
|
24.34
|
14.29
|
34.71
|
33.25
|
39.48
|
17.87
|
Operating Margin
|
9.79%
|
1.4%
|
-0.5%
|
5.52%
|
1.98%
|
5.63%
|
1.71%
|
6.05%
|
10.76%
|
5.79%
|
3.39%
|
7.92%
|
7.66%
|
8.57%
|
3.89%
|
Earnings before Tax (EBT)
1 |
26.43
|
3.34
|
9.859
|
17.23
|
8.635
|
7.243
|
-13.15
|
13.94
|
31.29
|
6.73
|
3.692
|
27.71
|
24.58
|
29.47
|
11.38
|
Net income
1 |
16.22
|
-3.823
|
3.013
|
7.905
|
0.668
|
-0.934
|
-21
|
8.369
|
17.54
|
-1.858
|
-3.744
|
14.47
|
12.24
|
15.74
|
1.772
|
Net margin
|
4.88%
|
-1.15%
|
0.88%
|
2.23%
|
0.19%
|
-0.24%
|
-5.38%
|
2.07%
|
4.36%
|
-0.44%
|
-0.89%
|
3.3%
|
2.82%
|
3.42%
|
0.39%
|
EPS
2 |
0.3000
|
-0.0700
|
0.0500
|
0.1300
|
0.0100
|
-0.0200
|
-0.3600
|
0.1200
|
0.2500
|
-0.0300
|
-0.0550
|
0.1950
|
0.1650
|
0.2100
|
0.0250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-08
|
22-03-01
|
22-05-09
|
22-08-09
|
22-11-09
|
23-03-01
|
23-05-09
|
23-08-08
|
23-11-08
|
24-02-29
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
30.2
|
140
|
11.6
|
27
|
44.3
|
76.9
|
93.3
|
ROE (net income / shareholders' equity)
|
10.6%
|
-
|
12.5%
|
4.28%
|
-
|
4.1%
|
5.7%
|
ROA (Net income/ Total Assets)
|
1.07%
|
-
|
1.29%
|
0.54%
|
-
|
1.5%
|
2.2%
|
Assets
1 |
1,377
|
-
|
1,923
|
1,989
|
-
|
2,580
|
2,578
|
Book Value Per Share
|
3.010
|
3.210
|
4.270
|
5.770
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
73
|
93.3
|
138
|
119
|
177
|
136
|
155
|
Capex / Sales
|
6.32%
|
8.71%
|
10.48%
|
8.35%
|
10.92%
|
7.76%
|
8.17%
|
Announcement Date
|
20-03-12
|
21-03-08
|
22-03-01
|
23-03-01
|
24-02-29
|
-
|
-
|
Last Close Price
51.69
USD Average target price
53.33
USD Spread / Average Target +3.18% Consensus |
1st Jan change
|
Capi.
|
---|
| +48.66% | 3.73B | | -19.14% | 8.22B | | -8.06% | 2.46B | | -38.71% | 2.46B | | -8.84% | 2.36B | | -9.02% | 1.78B | | -19.29% | 1.52B | | -40.78% | 1.21B | | +8.32% | 1.12B | | -12.27% | 1.09B |
Medical & Diagnostic Laboratories
|